How antibody drug conjugates are changing the game of precision oncology
ADCs target cancer cells with precision, offering a promising advance in minimizing treatment side effects.
ADCs target cancer cells with precision, offering a promising advance in minimizing treatment side effects.
While this isn't ideal news, it would be much worse if we didn't know.
It was safe and showed efficacy for 97% of the participants in the trial.
It's not ideal, but it's better than some expected.
An important step forward in the fight to eradicate Ebola.
Just 3% of the world's population has antibodies for COVID-19 -- woefully short of at least 60% required for herd ...
The antibodies were isolated a few years ago, but there was "no need for such a treatment" at the time.
It's good news for sufferers of epilepsy -- though novel treatments are still a while away.
Their nature makes them ideal against pathogens that hide from immune cells, such as HIV.
Mostly affecting those 60 years old and older, an estimated 7 to 10 million people worldwide have Parkinson's Disease.
Scientists from the Scripps Research Institute (TSRI) and Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have discovered a way ...